Catalyst Pharmaceuticals (CPRX) EBIAT (2016 - 2025)
Historic EBIAT for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $52.8 million.
- Catalyst Pharmaceuticals' EBIAT rose 2027.85% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 5235.89%. This contributed to the annual value of $163.9 million for FY2024, which is 12950.43% up from last year.
- As of Q3 2025, Catalyst Pharmaceuticals' EBIAT stood at $52.8 million, which was up 2027.85% from $52.1 million recorded in Q2 2025.
- Catalyst Pharmaceuticals' 5-year EBIAT high stood at $56.7 million for Q1 2025, and its period low was -$30.8 million during Q3 2023.
- Its 5-year average for EBIAT is $27.3 million, with a median of $25.5 million in 2022.
- Per our database at Business Quant, Catalyst Pharmaceuticals' EBIAT plummeted by 23523.83% in 2023 and then skyrocketed by 24264.73% in 2024.
- Catalyst Pharmaceuticals' EBIAT (Quarter) stood at $9.3 million in 2021, then soared by 173.62% to $25.5 million in 2022, then soared by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then dropped by 5.64% to $52.8 million in 2025.
- Its last three reported values are $52.8 million in Q3 2025, $52.1 million for Q2 2025, and $56.7 million during Q1 2025.